Rotavirus

Emerg Infect Dis. Oct-Dec 1998;4(4):561-70. doi: 10.3201/eid0404.980406.

Abstract

Rotavirus, the most common diarrheal pathogen in children worldwide, causes approximately one third of diarrhea-associated hospitalizations and 800,000 deaths per year. Because natural infection reduces the incidence and severity of subsequent episodes, rotavirus diarrhea might be controlled through vaccination. Serotypespecific immunity may play a role in protection from disease. Tetravalent rhesus-human reassortant rotavirus vaccine (RRV-TV) (which contains a rhesus rotavirus with serotype G3 specificity and reassortant rhesus-human rotaviruses with G1, G2, and G4 specificity) provides coverage against the four common serotypes of human rotavirus. In clinical trials in industrialized countries, RRV-TV conferred 49% to 68% protection against any rotavirus diarrhea and 61% to 100% protection against severe disease. This vaccine was licensed by the U.S. Food and Drug Administration on August 31, 1998, and should be cost-effective in reducing diarrheal diseases in industrialized countries. The vaccine's efficacy and cost-effectiveness in developing countries should be evaluated.

Publication types

  • Review

MeSH terms

  • Animals
  • Humans
  • Rotavirus / immunology
  • Rotavirus / ultrastructure
  • Rotavirus Infections / epidemiology
  • Rotavirus Infections / immunology
  • Rotavirus Infections / physiopathology
  • Rotavirus Infections / prevention & control*
  • Viral Vaccines / immunology*

Substances

  • Viral Vaccines